Page 218 - Haematologica Vol. 110 - January 2025

LETTER TO THE EDITOR
We also studied the value of genomic complexity to stratify adult T-ALL patients, based on the number of CNV and SNV per patient, which could provide information of the plasticity of blast cell. We showed that an increased number of >14alt was associated with worse outcomes, similarly to what has been described with karyotype studies.14,15 This may be due to the higher genetic heterogeneity of leukemic cells in these patients, which provides more opportunities for the leuke- mia to evade treatment. However, limitations in the cohort size, precluded the evaluation of the prognostic impact of this genetic marker by multivariable analysis.
In summary, herein we show that CNV, that are essential for T-cell leukemia development, help to improve genetic risk stratification of T-ALL. Further studies in larger T-ALL cohorts with complete genomic data (i.e., inclusion of re- arrangements) are needed to confirm our findings and to delineate an integrative genetic approach to assess clinically relevant onco-genetic pathways.
Authors
Celia González-Gil,1 Mireia Morgades,2+ Thaysa Lopes,1+ Francisco Fuster-Tormo,1° Pau Montesinos,3 Pere Barba,4 Marina Díaz-Beya,5 Lourdes Hermosín,6 Clara Maluquer,7 José González-Campos,8 Teresa Bernal,9 Marta Sitges Arriaga,10 Lurdes Zamora,2 Marta Pratcorona,11 Rodrigo Martino,11 María José Larrayoz,12 Teresa Artola,13 Anna Torrent,2 Ferran Vall-llovera,14 Mar Tormo,15 Cristina Gil,16 Andrés Novo,17 Pilar Martínez-Sánchez,18 Jordi Ribera,1 María-Paz Queipo,19 Teresa González- Martínez,20 Mónica Cabrero,20 Antonia Cladera,21 José Cervera,3 Alberto Orfao,22 Josep Maria Ribera1,2 and Eulàlia Genescà1
1Institut d’Investigació contra la Leucemia Josep Carreras (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona; 2Departament d’Hematologia Clínica, ICO- Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona; 3Hospital Universitari i Politècnic La Fe, Valencia; 4Servei Hematologia Clínica, Hospital Universitari de la Vall d’Hebron, Barcelona; 5Servei Hematologia Clínica, Hospital Clínic de Barcelona, Barcelona; 6Servicio Hematología Clínica, Hospital de Jerez, Jerez de la Frontera; 7Servei Hematologia Clínica, Hospital Duran i Reynals-ICO, Hospitalet del Llobregat, Llobregat; 8Servicio Hematología Clínica, Hospital Virgen del Rocío, Sevilla; 9Servicio Hematología Clínica, Hospital Central de Asturias, Instituto de Investigación Sanitario del Principado de Asturias (ISPA), Instituto Oncológico Universitario del Principado de Asturias (IUOPA), Oviedo; 10Institut Català d’Oncologia (ICO), Hospital Josep Trueta, Girona; 11Servei Hematologia, Hospital de la Santa Creu i Sant Pau, Barcelona; 12Laboratorio Enfermedades Hematológica, CIMA, Navarra; 13Servicio Hematología Clínica, Hospital Universitario de Donostia, Donostia; 14Servei Hematologia Clínica, Hospital Mútua de Terrassa, Terrassa; 15Hospital Clínico Universitario, Instituto de investigación INCLIVA, Valencia; 16Servicio Hematología Clínica, Hospital General de Alicante, Alicante; 17Servicio Hematología Clínica, Hospital Son Espases, Palma de Mallorca; 18Servicio Hematología Clínica, Hospital 12 de Octubre, Madrid; 19Servicio
Hematología Clínica, Hospital Virgen de la Victoria, Málaga; 20Servicio Hematología Clínica, Hospital Universitario de Salamanca, Salamanca; 21Servicio Hematología Clínica, Hospital Son Llátzer, Palma de Mallorca and 22Centro de Investigación del Cáncer (IBMCC-CSIC/USAL) and Departamento de Medicina, Universidad de Salamanca, Instituto Biosanitario de Salamanca, CIBERONC, Salamanca, Spain
+MM and TL contributed equally.
°Current address: Technology and Development Team, Veritas
Intercontinental, Barcelona, Spain
Correspondence:
E.G. FERRER - egenesca@carrerasresearch.org
https://doi.org/10.3324/haematol.2024.285416
Received: March 6, 2024. Accepted: August 1, 2024. Early view: August 8, 2024.
©2025 Ferrata Storti Foundation Published under a CC BY-NC license
Disclosures
No conflicts of interests to disclose.
Contributions
CG-C analyzed the data, produced the figures and wrote the paper. MM did the statistical analyses. TL collected and prepared DNA samples. FF-T optimized CNV analysis. PM, PB, MD-B, LH, CM, JG-C, TB., MS, LZ, MP, RM, MJL, TA, AT, FV-Ll, M T, CG, AN, PM-S, JR, M-PQ, TG-M, MC, AC and JC provided clinical data and/or DNA samples. AO and J MR reviewed the manuscript. EG designed the study, reviewed the data, co-wrote and reviewed the manuscript.
Acknowledgments
We would like to thank María Jesús Vidal, Rosa Fernández-Martín, Irene García-Cadenas, Gemma Azaceta, Aurelio López Martínez, Marta Valero, Beatriz Soria, Álvaro Bienert, Silvia Monsalvo, Ignacio Gómez Centurión, María Lourdes Amador, Xavier Ortín, Jesús Feliu, Carlos Rodríguez, María-Paz Martínez, and Ma Jesús Peñarrubia for providing retrospective clinical data for this study.
Funding
This project was supported by the AECC (GC16173697BIGA); ISCIII (PI19/01828 and PI19/01183), co-funded by ERDF/ESF, “A way to make Europe”/”Investing in your future”, 2021 SGR 00560 (GRC)/CERCA Program/Generalitat de Catalunya. CG-G was supported by SEHH grant (2021). TL was supported by the Leukemia Stiftung (DJCLS 08 R/2022).
Data-sharing statement
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Haematologica | 110 January 2025
210